NSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,479.40
- Market cap
- ₹69,975 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 38.9×Sector 37.9×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 42,473 Mn, down 29.8% YoY on a reported basis. EBITDA Rs 8,638 Mn (20.3% margin); Adj PAT Rs 4,852 Mn (11.4% margin). North America headline is flattered by ISB 2001 licensing income.
Glenmark Pharmaceuticals Q2 FY27 Results: Net Profit ₹263.8 Cr, Down 56.8% YoY
Glenmark Pharmaceuticals Ltd reported revenue from operations of ₹4,247 Cr (-29.8% YoY) and net profit of ₹263.8 Cr (-56.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹263.8 Cr · -56.8% YoY
Glenmark Pharmaceuticals Other Announcement
Glenmark's partner IGI will present updated Phase 1 clinical data for ISB 2001 (ABBV-2001) in relapsed/refractory multiple myeloma at the 68th ASH Annual Meeting. The presentation is scheduled for December 12, 2026.
Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Other Announcement
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Other results update announcements
All →Hindustan Foods Results Update
Hindustan Foods' H1 FY27 adjusted PAT rose 30% to Rs 89 crore, and it reaffirmed FY27 guidance. Silvassa floods and project delays are weighing on near term.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
HPL Electric & Power Results Update
HPL Electric & Power reported record Q2 FY27 revenue, up 40% year-on-year, and crossed ₹600 crore for the first time. Margins narrowed on input-cost volatility and a shift in revenue mix.
India Homes Results Update
India Homes reported Q2 FY27 revenue of ₹28.13 lakh and PAT of ₹426.66 lakh. Profit reversed a prior-year loss; PAT includes exceptional items.
Aditya Birla Fashion and Retail Results Update
ABFRL's Q2 FY27 revenue rose 2% to Rs 2,030 Crore, but EBITDA fell 43% amid a festive date shift. Press release accompanies unaudited quarter results.
RateGain Travel Technologies Results Update
RateGain reported Q2 FY27 operating revenue of INR 745.4 Cr, up 152.6% YoY, with adjusted EBITDA margin at 22.7%. Adjusted PAT rose 78% YoY to INR 90.8 Cr.